PD-L1 Antibody (130021) [Unconjugated]

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Human B7 homolog 1 (B7-H1), also called programmed death ligand 1 (PD-L1) and programmed cell death 1 ligand 1 (PDCD1L1), is a member of the growing B7 family of immune proteins that provide signals for both stimulating and inhibiting T cell activation. Other family members include B7-1, B7-2, B7-H2, PDL2 and B7-H3. B7 proteins are members of the immunoglobulin (Ig) superfamily. Their extracellular domains contain 2 Ig-like domains and all members have short cytoplasmic domains. Among the family members, there is about 20-25% amino acid identity. Human and mouse B7-H1 share approximately 70% amino acid sequence identity. B7-H1 has been identified as one of two ligands for programmed death-1 (PD-1), a member of the CD28 family of immunoreceptors. The B7-H1 gene encodes a 291 amino acid (aa) type I membrane precursor protein with a putative 18 aa signal peptide, a 220 aa extracellular domain, a 21 aa transmembrane region, and a 31 aa cytoplasmic domain. Human B7-H1 is constitutively expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. B7-H1 expression is upregulated in a small fraction of activated T and B cells and a much larger fraction of activated monocytes. B7-H1 expression is also induced in dendritic cells and keratinocytes after IFN-gamma stimulation. Interaction of B7-H1 with PD-1 results in inhibition of TCR-mediated proliferation and cytokine production. The B7-H1:PD-1 pathway is involved in the negative regulation of some immune responses and may play an important role in the regulation of peripheral tolerance.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 8 applications: ELISA Detection, ELISA Development (Capture), Flow Cytometry, ICC, IF, IHC, IHC-P, Western Blot.

Showing Publications 1 - 10 of 24. Show All 24 Publications. Collapse Publications.

Publications using MAB1561	Applications	Species
Q Niu, J Gao, K Zhao, X Chen, X Lin, C Huang, Y An, X Xiao, Q Wu, L Cui, P Zhang, L Wu, C Yang Fluid nanoporous microinterface enables multiscale-enhanced affinity interaction for tumor-derived extracellular vesicle detection Proceedings of the National Academy of Sciences of the United States of America, 2022-10-28;119(44):e2213236119. 10/28/2022 [PMID: 36306324]
X Hou, X Shi, J Luo Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer Oncology Letters, 2022-05-17;24(1):215. 2022-05-17 [PMID: 35720491] (IHC, Human)	IHC	Human
David Labib, Zhen Wang, Priya Prakash, Matthew Zimmer, Matthew D. Smith, Paul W. Frazel et al. Proteomic Alterations and Novel Markers of Neurotoxic Reactive Astrocytes in Human Induced Pluripotent Stem Cell Models Frontiers in Molecular Neuroscience 2022-05-03 [PMID: 35592112]
YM Chung, WB Tsai, PP Khan, J Ma, JS Berek, JW Larrick, MC Hu FOXO3-dependent suppression of PD-L1 promotes anticancer immune responses via activation of natural killer cells American journal of cancer research, 2022-03-15;12(3):1241-1263. 2022-03-15 [PMID: 35411241] (IF, Human)	IF	Human
Young Min Chung, Pragya P Khan, Hong Wang, Wen-Bin Tsai, Yanli Qiao, Bo Yu et al. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3 Journal for ImmunoTherapy of Cancer 2021-12-08 [PMID: 34887262]
A Eljaafari, J Pestel, B Le Maguere, S Chanon, J Watson, M Robert, E Disse, H Vidal Adipose-Tissue-Derived Mesenchymal Stem Cells Mediate PD-L1 Overexpression in the White Adipose Tissue of Obese Individuals, Resulting in T Cell Dysfunction Cells, 2021-10-03;10(10):. 2021-10-03 [PMID: 34685625] (IHC, Human)	IHC	Human
A Makowska, N Lelabi, C Nothbaum, L Shen, P Busson, TTB Tran, M Eble, U Kontny Radiotherapy Combined with PD-1 Inhibition Increases NK Cell Cytotoxicity towards Nasopharyngeal Carcinoma Cells Cells, 2021-09-17;10(9):. 2021-09-17 [PMID: 34572108] (Flow Cytometry, Human)	Flow Cytometry	Human
James W Opzoomer, Jessica A Timms, Kevin Blighe, Thanos P Mourikis, Nicolas Chapuis, Richard Bekoe et al. ImmunoCluster provides a computational framework for the nonspecialist to profile high-dimensional cytometry data eLife 2021-04-30 [PMID: 33929322]
T Mocan, M Ilies, I Nenu, R Craciun, A Horhat, R Susa, I Minciuna, I Rusu, LP Mocan, A Seicean, CA Iuga, NA Hajjar, M Sparchez, DC Leucuta, Z Sparchez Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma International immunopharmacology, 2021-02-18;94(0):107467. 2021-02-18 [PMID: 33611059] (IHC, Human)	IHC	Human
E Acheampong, A Abed, M Morici, S Bowyer, B Amanuel, W Lin, M Millward, ES Gray Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis Cells, 2020-10-31;9(11):. 2020-10-31 [PMID: 33142852] (IHC, Human)	IHC	Human
Xin Cui, Chao Ma, Varshini Vasudevaraja, Jonathan Serrano, Jie Tong, Yansong Peng et al. Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy eLife 2020-09-10 [PMID: 32909947]
Y Tian, X Zhai, A Han, H Zhu, J Yu Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer J Hematol Oncol, 2019-06-28;12(1):67. 6/28/2019 [PMID: 31253167]
R Giampieri, F Piva, G Occhipinti, A Bittoni, A Righetti, S Pagliarett, A Murrone, F Bianchi, C Amantini, M Giulietti, G Ricci, G Principato, G Santoni, R Berardi, S Cascinu Clinical impact of different exosomes' protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy PLoS ONE, 2019-05-02;14(5):e0215990. 2019-05-02 [PMID: 31048929] (ELISA Detection, Human)	ELISA Detection	Human
CM Cristiani, A Turdo, V Ventura, T Apuzzo, M Capone, G Madonna, D Mallardo, C Garofalo, ED Giovannone, AM Grimaldi, R Tallerico, E Marcenaro, S Pesce, G Del Zotto, V Agosti, FS Costanzo, E Gulletta, A Rizzo, A Moretta, K Kärre, PA Ascierto, M Todaro, E Carbone Accumulation of circulating CCR7+ natural killer cells marks melanoma evolution and reveals a CCL19-dependent metastatic pathway Cancer Immunol Res, 2019-04-02;0(0):. 2019-04-02 [PMID: 30940644] (ICC, IHC-P, Human)	ICC, IHC-P	Human
Mathilde Dusséaux, Guillemette Masse-Ranson, Sylvie Darche, James Ahodantin, Yan Li, Oriane Fiquet et al. Viral Load Affects the Immune Response to HBV in Mice With Humanized Immune System and Liver Gastroenterology 2017-12-01 [PMID: 28851562]
SF Kammerer-J, A Brunot, K Bensalah, B Campillo-G, M Lefort, S Bayat, A Ravaud, F Dupuis, M Yacoub, G Verhoest, B Peyronnet, R Mathieu, A Lespagnol, J Mosser, J Edeline, B Laguerre, JC Bernhard, N Rioux-Lecl Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment Urol. Oncol., 2017-06-12;0(0):. 2017-06-12 [PMID: 28619630] (IHC-P, Human)	IHC-P	Human
J Zhou, KM Mahoney, A Giobbie-Hu, F Zhao, S Lee, X Liao, S Rodig, J Li, X Wu, LH Butterfiel, M Piesche, MP Manos, LM Eastman, G Dranoff, GJ Freeman, FS Hodi Soluble PD-L1 as a biomarker in malignant melanoma and checkpoint blockade Cancer Immunol Res, 2017-05-18;0(0):. 2017-05-18 [PMID: 28522460] (ELISA Development (Capture), Human)	ELISA Development (Capture)	Human
Stéphane Chevrier, Jacob Harrison Levine, Vito Riccardo Tomaso Zanotelli, Karina Silina, Daniel Schulz, Marina Bacac et al. An Immune Atlas of Clear Cell Renal Cell Carcinoma Cell 2017-05-04 [PMID: 28475899]
Marlon C. Rebelatto, Anita Midha, Amita Mistry, Constantine Sabalos, Nicole Schechter, Xia Li et al. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma Diagnostic Pathology 2016-12-01 [PMID: 27717372]
Kammerer-Jacquet S, Crouzet L, Brunot A, Dagher J, Pladys A, Edeline J, Laguerre B, Peyronnet B, Mathieu R, Verhoest G, Patard J, Lespagnol A, Mosser J, Denis M, Messai Y, Gad-Lapiteau S, Chouaib S, Belaud-Rotureau M, Bensalah K, Rioux-Leclercq N Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential. Int J Cancer, 2016-09-23;140(1):142-148. 2016-09-23 [PMID: 27623354] (IHC-P, Human)	IHC-P	Human
Zoran Gatalica, Nurija Bilalovic, Juan P. Palazzo, Ryan P. Bender, Jeffrey Swensen, Sherri Z. Millis et al. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1 Oncotarget 2015-06-08 [PMID: 26110571]
Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L, Rossille D, Maudelonde T, Fest T, Alix-Panabieres C Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol, 2015-06-09;9(9):1773-82. 2015-06-09 [PMID: 26093818] (Western Blot, Human)	Western Blot	Human
Song , Xiao, Liu , Junwei, Lu , Yi, Jin , Hongchua, Huang , Dongshen Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer. Oncol Rep, 2013-12-31;31(3):1191-8. 2013-12-31 [PMID: 24378899] (IHC, Human)	IHC	Human
Rojas D, Krishnan R IFN-gamma generates maturation-arrested dendritic cells that induce T cell hyporesponsiveness independent of Foxp3+ T-regulatory cell generation. Immunol. Lett., 2010-05-24;132(1):31-7. 2010-05-24 [PMID: 20580745] (Flow Cytometry, Human)	Flow Cytometry	Human
Show All 24 Publications. Collapse Publications.

Array MAB1561

• PD-L1 Antibodies
• PD-L1 Antibody Pairs
• PD-L1 Lysate
• PD-L1 Proteins
• PD-L1 Proteins and Enzymes
• PD-L1 ELISAs